June CHMP meeting sees seven novel drugs recommended for approval

24 June 2022

The European Medicines Agency’s human medicines committee (CHMP) recommended seven novel medicines for approval at its June 2022 meeting, including the first gene therapy for hemophilia A.

The committee adopted a positive opinion for Pepaxti (melphalan flufenamide), from Swedish biotech Oncopeptides (Nasdaq Stockholm: ONCO), for the treatment of multiple myeloma, a rare cancer of the bone marrow that affects plasma cells, a type of white blood cell that produces antibodies.

US pharma major Eli Lilly’s (NYSE: LLY) Rayvow (lasmiditan), intended for the treatment of migraine in adults, received a positive opinion from the CHMP. It is estimated that approximately 15% of the EU population suffers from migraine, according to the EMA.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK